论文部分内容阅读
玻璃体内应用抗PVR药物缓释制剂已成为近年研究的热点。本文依照有、无载体、制剂的释药方式等特点分别介绍玻璃体内各种抗PVR药物缓释制剂及其优缺点。其依照有、无载体可分为两类 :一类是以高分子聚合物为载体的缓释制剂 ,另一类是无载体的抗PVR药物联合制剂。前者按照其释药方式又可分为延缓释放制剂和控释给药制剂 ,后者依据其剂型不同又可分为联合粉剂与联合片剂、注射用粉剂与植入用片剂。它们各有所长 ,但均有不足之处。理想的缓释制剂应是尽量具有持效时间长、释药恒速、位置固定、自行降解、容易消毒、使用方便及良好的生物相容性。
Intravitreal anti-PVR drug delivery has become a research hotspot in recent years. In this paper, according to there, no carrier, the release of the preparation and other characteristics were introduced intravitreal various anti-PVR drug sustained-release preparations and their advantages and disadvantages. According to their own, no carrier can be divided into two categories: one is a polymer-based sustained-release carrier, the other is a carrier-free anti-PVR drug combination. The former can be divided into delayed release preparation and controlled release preparation according to the mode of its release, the latter can be divided into combined powder and united tablet, injection powder and implanted tablet according to different dosage forms. They have their own advantages, but they all have some shortcomings. The ideal sustained-release preparation should be as long as the persistence time, drug release constant speed, fixed position, self-degradation, easy to disinfect, easy to use and good biocompatibility.